Frontiers Journal of Neurology & Neuroscience

Changing The Game: A New Class Of Anti-migraine Drugs

Abstract

Background: Migraine headaches are a severe and disabling neurovascular disorder affecting nearly 20% of adults in the United States1. Calcitonin Gene Related Peptide (CGRP) monoclonal antibodies (mAB) is a new class of anti-migraine drugs that represent the first targeted therapy for the prevention of migraine. 

COPYRIGHT© FRONTIERSMEETINGS 2019. ALL RIGHTS RESERVED | TERMS AND CONDITIONS